Torthaí cuardaigh - Anne‐Laure Sellier‐Leclerc

  • 1 - 11 toradh as 11 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome

    Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome de réir Anne‐Laure Sellier‐Leclerc, Emré Belli, Valérie Guérin, Peter Dorfmüller, Georges Deschênes

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3

    Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3 de réir Jaap W. Groothoff, Anne‐Laure Sellier‐Leclerc, Lisa J. Deesker, Justine Bacchetta, Gesa Schalk, Burkhard Tönshoff, Graham Lipkin, Sandrine Lemoine, Thomas Bowman, Jing Zhou, Bernd Höppe

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    A Humanized Mouse Model of Idiopathic Nephrotic Syndrome Suggests a Pathogenic Role for Immature Cells

    A Humanized Mouse Model of Idiopathic Nephrotic Syndrome Suggests a Pathogenic Role for Immature Cells de réir Anne‐Laure Sellier‐Leclerc, Arnaud Duval, SteCombining Acute Accentphanie Riveron, Marie-Alice Macher, Georges Deschênes, Chantal Loirat, Marie‐Christine Verpont, Michel Peuchmaur, Pierre Ronco, Renato C. Monteiro, Élie Haddad

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial

    Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial de réir Wesley Hayes, David J. Sas, Daniella Magen, Hadas Shasha‐Lavsky, Mini Michael, Anne‐Laure Sellier‐Leclerc, Julien Hogan, Taylor Ngo, Marianne T. Sweetser, John M. Gansner, Tracy L. McGregor, Yaacov Frishberg

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Differential Impact of Complement Mutations on Clinical Characteristics in Atypical Hemolytic Uremic Syndrome

    Differential Impact of Complement Mutations on Clinical Characteristics in Atypical Hemolytic Uremic Syndrome de réir Anne‐Laure Sellier‐Leclerc, Véronique Frémeaux‐Bacchi, Marie‐Agnès Dragon‐Durey, Marie-Alice Macher, Patrick Niaudet, Geneviève Guest, B. Boudailliez, F Bouissou, Georges Deschênes, Sophie Gié, Michel Tsimaratos, Michel Fischbach, Denis Morin, Hubert Nivet, Corinne Alberti, Chantal Loirat

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Complement Gene Variants and Shiga Toxin–Producing Escherichia coli–Associated Hemolytic Uremic Syndrome

    Complement Gene Variants and Shiga Toxin–Producing Escherichia coli–Associated Hemolytic Uremic Syndrome de réir Véronique Frémeaux‐Bacchi, Anne‐Laure Sellier‐Leclerc, Paula Vieira‐Martins, Sophie Limou, Thérèsa Kwon, Annie Lahoche, Robert Novo, Brigitte Llanas, François Nobili, G. Roussey, Mathilde Cailliez, Tim Ulinski, Georges Deschênes, Corinne Alberti, François‐Xavier Weill, Patricia Mariani, Chantal Loirat

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial

    Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial de réir Mini Michael, Jaap W. Groothoff, Hadas Shasha‐Lavsky, John C. Lieske, Yaacov Frishberg, Eva Šimková, Anne‐Laure Sellier‐Leclerc, Arnaud Devresse, Fitsum Guebre‐Egziabher, Sevcan A. Bakkaloğlu, Chebl Mourani, Rola Saqan, Richard Singer, Richard E. Willey, Bahru Habtemariam, John M. Gansner, Ishir Bhan, Tracy L. McGregor, Daniella Magen

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy

    Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy de réir Sophie Chauvet, Jill J. Hauer, Florent Petitprez, Marion Rabant, Paula Vieira Martins, Véronique Baudouin, Yahsou Delmas, Noémie Jourde‐Chiche, Alexandre Cez, David Ribes, Sylvie Cloarec, Aude Servais, Mohamad Zaidan, Éric Daugas, Michel Delahousse, Alain Wynckel, Amélie Ryckewaert, Anne Laure Sellier-Leclerc, Olivia Boyer, Éric Thervet, Alexandre Karras, Richard J. Smith, Véronique Frémeaux‐Bacchi

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Real-world use of complement inhibitors for haemolytic uraemic syndrome: an analysis of the European Rare Kidney Disease Registry cohort

    Real-world use of complement inhibitors for haemolytic uraemic syndrome: an analysis of the European Rare Kidney Disease Registry cohort de réir Aleksandra Vujović, Anne‐Laure Sellier‐Leclerc, Maria Cristina Mancuso, Olivia Boyer, Atif Awan, Antonio Gargiulo, Sebastian Loos, Marc Fila, Augustina Jankauskiené, Gema Ariceta, Nele Kanzelmeyer, Enrico Vidal, Maria Van Dyck, Tanja Kersnik Levart, N Simánková, Stéphane Decramer, Jonas Hofstetter, Marina Vivarelli, Savino Sciascia, Nicole C. A. J. van de Kar, Franz Schaefer

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

    Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study de réir Fádi Fakhouri, Marc Fila, Aurélie Hummel, David Ribes, Anne‐Laure Sellier‐Leclerc, Simon Ville, Claire Pouteil‐Noble, Jean‐Philippe Coindre, Moglie Le Quintrec, Éric Rondeau, Olivia Boyer, François Provôt, D. Djeddi, William Hanf, Yahsou Delmas, Férielle Louillet, Annie Lahoche, Guillaume Favrè, Valérie Châtelet, Emma Allain Launay, Claire Presne, Ariane Zaloszyc, Sophie Caillard, Stéphane Bally, Quentin Raimbourg, Leïla Tricot, Christiane Mousson, Aurélie Le Thuaut, Chantal Loirat, Véronique Frémeaux‐Bacchi

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children

    Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children de réir David J. Sas, Daniella Magen, Wesley Hayes, Hadas Shasha‐Lavsky, Mini Michael, Indra Schulte, Anne‐Laure Sellier‐Leclerc, Jiandong Lu, Ali Seddighzadeh, Bahru Habtemariam, Tracy L. McGregor, Kenji P. Fujita, Yaacov Frishberg, Justine Bacchetta, Véronique Baudouin, Rachel Becker‐Cohen, Shimrit Tzvi Behr, Efrat Ben‐Shalom, Maria Berdaguer, Detlef Böckenhauer, Pierre Cochat, Martin Coenen, Carl H. Cramer, Georges Deschênes, Claire Dossier, Emilie Doye, Liat Feraru Feldman, Maximilian Hohenadel, Florentia Kaguelidou, Irina Libinson Zebegret, John C. Lieske, Anne Maisin, Dawn S. Milliner, Moran Plonsky Toder, Shirley Pollack, Aurélie Portefaix, Bruno Ranchin, Choni Rinat, Adnan Safdar, Gesa Schalk, Poyyapakkam Srivaths, Cheryl L. Tran, William van’t Hoff, Jenny Weinbrand-Goichberg, Irith Weissman

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: